info
"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons. Find out more >>
FDA Approves First New Schizophrenia Drug in Over 30 Years
- summary
- score
The FDA approved Cobenfy, the first new schizophrenia drug in over 30 years. Unlike older antipsychotics, which alter dopamine, Cobenfy adjusts acetylcholine—a brain chemical affecting memory and attention. This shift may reduce common side effects like weight gain and drowsiness. In trials, only 6% of patients stopped Cobenfy due to side effects, compared to 20-30% with older drugs. Schizophrenia affects about 24 million people globally. Further studies aim to test Cobenfy for Alzheimer's and bipolar disorder.
| Scores | Value | Explanation |
|---|---|---|
| Objectivity | 6 | Comprehensive reporting with in-depth analysis. |
| Social Impact | 5 | Significantly influences public opinion on mental health. |
| Credibility | 5 | Solid evidence from authoritative sources. |
| Potential | 6 | High potential for major changes in treatment. |
| Practicality | 5 | Extremely practical, widely applicable. |
| Entertainment Value | 2 | Slightly monotonous, few entertaining elements. |